USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Transformation to pure-play Innovative Medicines company nears completion
The production suspension impacts commercial and clinical trial supply
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
